FSD Pharma Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
HUGE New York 8731 https://www.fsdpharma.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for FSD Pharma Inc

FSD Pharma Provides Update from Celly Nu’s Partnership with Six+One for unbuzzd(TM) - Apr 25th, 2024 11:47 am
FSD Pharma Provides Another Update on Celly Nu's Anticipated Launch of unbuzzd(TM) - Apr 22nd, 2024 12:00 pm
FSD Pharma Expands Investigative Pipeline to Include Potential Weight Loss and Liver Health Formulations and Products - Apr 17th, 2024 12:00 pm
FSD Pharma Provides Update on its Investment in Celly Nutrition Corp., a Company Launching a Product that can assist in Expediting Alcohol Metabolism and Faster Recovery from Alcohol Consumption - Apr 15th, 2024 12:00 pm
FSD Pharma Inc. Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency - Apr 8th, 2024 2:55 am
FSD Pharma Announces Filing of Year-End 2023 Results - Apr 2nd, 2024 2:00 am
FSD Pharma Signs the Agreement With iNGENu CRO To Conduct a Clinical Study To Assess the Safety and Pharmacokinetics of Multiple Ascending Doses of Lucid-21-302 (Lucid-MS) in Healthy Adults - Mar 27th, 2024 12:00 pm
FSD Pharma Submits a Phase-1b Clinical Trial Application for Ethics Committee for its Proprietary Beverage unbuzzd(TM) - Mar 11th, 2024 12:00 pm
FSD Pharma Presents Positive Results on First-In-Human Phase-1 study of Lucid-21-302 (Lucid-MS) at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2024 Forum - Mar 5th, 2024 1:00 pm
FSD Pharma Announces Debt Settlement - Feb 28th, 2024 1:00 pm
FSD Pharma Signs Agreement With Ingenu CRO to Conduct a Clinical Trial To Determine the Safety and Efficacy Effects of its Proprietary Blend Beverage unbuzzd(TM) - Feb 26th, 2024 1:00 pm
FSD Pharma Announces US ATM Offering - Feb 17th, 2024 12:50 am
Court of Appeal Dismisses Motion for Leave to Appeal Brought by Dr. Raza Bokhari, FSD Pharma Awards Total Approximately $3 Million - Feb 6th, 2024 12:00 pm
FSD Pharma Announces Dr. Sanjiv Chopra is elected to FSD Pharma Board of Directors and Corporate Updates - Jan 29th, 2024 9:30 pm
Update Provided on GBB Drink Lab, Inc. Litigation and Safety Shot - Jan 16th, 2024 12:30 pm
GBB Maintains Strong Position in its Ongoing Lawsuit with FSD Pharma After Court Refuses to Dismiss Case - Jan 11th, 2024 6:10 pm
FSD Pharma Files Final Base Shelf Prospectus to Replace Expired Base Shelf Prospectus and Form F-3 Registration Statement with the SEC - Dec 23rd, 2023 12:45 am
FSD Pharma Inc. Announces Closing of Private Placement - Dec 5th, 2023 2:00 pm
FSD Pharma Inc. and Celly Nutrition Corp. Announce Completion of Plan of Arrangement - Nov 30th, 2023 1:30 pm
Update Provided on GBB Drink Lab, Inc. Litigation and Safety Shot Previously known as Jupiter Wellness - Nov 28th, 2023 2:00 pm